Genmab A/S (NASDAQ:GMAB) has received an average rating of “Buy” from the six analysts that are covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $23.00.
Several research analysts have recently weighed in on the stock. Royal Bank of Canada assumed coverage on shares of Genmab A/S in a report on Monday, August 12th. They issued an “outperform” rating and a $23.00 price target on the stock. Guggenheim assumed coverage on shares of Genmab A/S in a report on Monday, August 12th. They issued a “buy” rating on the stock. Morgan Stanley assumed coverage on shares of Genmab A/S in a report on Monday, August 12th. They issued an “overweight” rating on the stock. JPMorgan Chase & Co. raised shares of Genmab A/S from a “neutral” rating to an “overweight” rating and set a $23.00 price target on the stock in a report on Thursday. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Genmab A/S in a report on Monday, August 26th.
A hedge fund recently bought a new stake in Genmab A/S stock. Private Capital Group LLC bought a new position in Genmab A/S (NASDAQ:GMAB) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 2,680 shares of the company’s stock, valued at approximately $41,000. 0.83% of the stock is currently owned by institutional investors.
Genmab A/S stock opened at $20.37 on Friday. Genmab A/S has a fifty-two week low of $12.10 and a fifty-two week high of $21.45.
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Read More: Cash Asset Ratio
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.